A case of pancreatic cancer in the setting of autoimmune pancreatitis with nondiagnostic serum markers by Chandrasegaram, M. et al.
PUBLISHED VERSION  
 
Manju D. Chandrasegaram, Su C. Chiam, Nam Q. Nguyen, Andrew Ruszkiewicz, Adrian Chung, Eu L. 
Neo, John W. Chen, Christopher S. Worthley, and Mark E. Brooke-Smith 
A case of pancreatic cancer in the setting of autoimmune pancreatitis with nondiagnostic serum 
markers 
Case Reports in Surgery, 2013; 2013:809023-1-809023-6 
Copyright © 2013 Manju D. Chandrasegaram et al. This is an open access article distributed under the 
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 



























 http://hdl.handle.net/2440/90128  
Hindawi Publishing Corporation
Case Reports in Surgery
Volume 2013, Article ID 809023, 6 pages
http://dx.doi.org/10.1155/2013/809023
Case Report
A Case of Pancreatic Cancer in the Setting of Autoimmune
Pancreatitis with Nondiagnostic Serum Markers
Manju D. Chandrasegaram,1 Su C. Chiam,1 Nam Q. Nguyen,2
Andrew Ruszkiewicz,3 Adrian Chung,4 Eu L. Neo,1 John W. Chen,1
Christopher S. Worthley,1 and Mark E. Brooke-Smith1
1 Hepatobiliary Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia
2 Department of Gastroenterology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia
3 Department of Surgical Pathology, SA Pathology, Adelaide, Australia
4Department of Gastroenterology, Flinders Medical Centre, Bedford Park, SA 5042, Australia
Correspondence should be addressed to Manju D. Chandrasegaram; manjudashini@yahoo.com
Received 9 April 2013; Accepted 15 May 2013
Academic Editors: G. Lal, N. D. Merrett, and S. Tatebe
Copyright © 2013 Manju D. Chandrasegaram et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Autoimmune pancreatitis (AIP) often mimics pancreatic cancer. The diagnosis of both conditions is difficult
preoperatively let alone when they coexist. Several reports have been published describing pancreatic cancer in the setting of AIP.
Case Report.The case of a 53-year-old man who presented with abdominal pain, jaundice, and radiological features of autoimmune
pancreatitis, with a “sausage-shaped” pancreas and bulky pancreatic head with portal vein impingement, is presented. He had a
normal serum IgG4 and only mildly elevated Ca-19.9. Initial endoscopic ultrasound-(EUS-) guided fine-needle aspiration (FNA)
of the pancreas revealed an inflammatory sclerosing process only. A repeat EUS guided biopsy following biliary decompression
demonstrated both malignancy and features of autoimmune pancreatitis. At laparotomy, a uniformly hard, bulky pancreas
was found with no sonographically definable mass. A total pancreatectomy with portal vein resection and reconstruction was
performed. Histology revealed adenosquamous carcinoma of the pancreatic head and autoimmune pancreatitis and squamous
metaplasia in the remaining pancreas. Conclusion. This case highlights the diagnostic andmanagement difficulties in a patient with
pancreatic cancer in the setting of serum IgG4-negative, Type 2 AIP.
1. Introduction
Sarles et al. described the first reported case of idiopathic
chronic pancreatitis with hypergammaglobulinemia second-
ary to an autoimmune process in 1961 [1]. It was, however,
not until 1995 when Yoshida et al. proposed autoimmune
pancreatitis (AIP) as a diagnostic entity [2]. AIP is char-
acterised by unique clinical, radiological, and histological
features. AIP commonly presents with obstructive jaundice
and enlargement of the pancreas and mimics pancreatic
cancer [3]. Several diagnostic criteria for AIP have been
proposed. There are very few cases reported in the literature
of both pancreatic cancer and autoimmune pancreatitis diag-
nosed together. Here, an unusual case of pancreatic cancer in
the setting of autoimmune pancreatitis is reported, and the
diagnostic and management dilemmas explored.
2. Case Report
A 53-year-old man presented initially to his general practi-
tioner with epigastric pain, jaundice, and significant weight
loss over the preceding 3 months. He had no significant past
medical or surgical history.He smoked 20 cigarettes a day and
denied regular alcohol consumption.On examination, hewas
clinically jaundiced and had a soft abdomenwith a nontender
palpable gall bladder.
His initial blood tests demonstrated deranged liver func-
tion (Bili 160 umol/L, GGT 617U/L, and ALP 649U/L, ALT
342U/L, AST 170U/L), while his CA19-9 was only mildy
raised at 81 kU/L (normal ref < 37). Serum IgG4 was not
raised at 0.31 g/L (normal ref < 1.50).
An ultrasound demonstrated biliary dilatation with no
obvious mass. Subsequent computed tomography (CT) of
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Figure 1: CT abdomen with “sausage-shaped” pancreas.
his abdomen showed a bulky pancreatic head and “sausage-
shaped” pancreas. His pancreatic duct was normal in cali-
bre (Figures 1 and 2). The portal and superior mesenteric
veins were significantly narrowed and impinged (Figure 3).
The radiological features suggested autoimmune pancreatitis,
though a malignant process could not be excluded.
He underwent endoscopic biliary decompression and
placement of a biliary stent for his symptomatic jaundice. His
intrahepatic and extrahepatic biliary tree was dilated to the
lower third of the common bile duct (CBD), at which point
the lower CBD appeared narrowed (Figure 4).
At time of ERCP, an endoscopic ultrasound (EUS) was
performed. There was a 33 × 45mm irregular hypoechoic
area seen within the head of the pancreas, above which the
CBD tapered (Figure 5). The pancreatic duct had a normal
calibre in its course. There was also calibre change of the
portal vein and superior mesenteric vein in the region of the
pancreatic head without clear evidence of invasion. Hypoe-
choic nodes measuring 10mm and 8mm were seen at the
peripancreatic head and celiac axis, respectively. EU-guided
fine-needle aspiration (FNA) biopsy of the head of the
pancreas performed revealed loosely fibrous stromal tissue
with mildly distorted, reactive ductal epithelial element, and
lymphocytic infiltration (Figure 6). Further FNA of the celiac
and peripancreatic nodes showed reactive lymphoid cells. No
malignant cells were identified in the biliary duct brushings
nor in the FNA sample.
Whilst waiting for his jaundice to settle prior to planned
resection given the clinical suspicion of a malignant process,
a repeat EUS and FNA of the pancreatic head was performed.
Similar appearances to the initial EUS were seen. Biopsies
revealed features of autoimmune pancreatitis, and adenocar-
cinoma was revealed from one biopsy specimen.
At planned laporatomy, he had, an indurated, hard and
diffusely enlarged pancreas without clear demarcation be-
tween the malignant tumour and autoimmune pancreatitis.
Therewas no sonographically definablemass, raising concern
that a pancreaticoduodenectomy may carry a risk of leaving
tumour behind. Also, given the markedly enlarged gland, it
would have been difficult to safely perform a pancreati-
cojejunostomy. With the positive preoperative pathology
findings to guide, a total pancreatectomy with portal vein
resection and partial superior mesenteric vein resection and
reconstruction with an interposition graft of splenic vein was
performed.
Histology revealed a moderately differentiated 30mm
adenosquamous carcinoma of the head of the pancreas with
invasion of the duodenal wall and metastases into 4 of 40
lymph nodes; margins were clear, and his portal vein was
clear with extensive changes of autoimmune pancreatitis
(Figures 7 and 8). The nonneoplastic portion of the pancreas
showed extensive chronic pancreatitis with features consis-
tent with autoimmune pancreatitis and squamous metaplasia
(Figure 9).
The patient was heparinised postoperatively, and a Dop-
pler ultrasound of his portal vein on the first postoperative
day revealed good flow through the graft. He recovered well
postoperatively with close management of blood sugar levels.
Hewas discharged home 2weeks postsurgery and is currently
undergoing adjuvant chemotherapy.
3. Discussion
Autoimmune pancreatitis (AIP) is a subset of chronic pan-
creatitis, which has been extensively reported from Japan,
Europe, and USA. Diagnostic criteria for AIP include the
Japan Pancreas Society Criteria [4], theMayoClinic’sHISORt
Criteria [5], the Korean criteria [6], and the Asian consensus
criteria [7]. Descriptions from Japan have been predomi-
nantly based on the presence of distinct clinical phenotypes:
(1) radiological imaging showing diffuse enlargement of
the pancreas with diffuse irregular narrowing of the
pancreatic duct,
(2) elevated levels of serum gamma globulin or the
presence of autoantibodies,
(3) histopathological examination of pancreas showing
periductal lymphoplasmacytic infiltration and fibro-
sis [4].
For a diagnosis of AIP, criteria 1 must be present, together
with criterion 2 and/or 3.
Subsequent studies fromEurope andUSA have described
2 distinct histopathologic patterns of AIP. Type 1 AIP is
lymphoplasmacytic sclerosing pancreatitis (LPSP) and has
also been called IgG4-related pancreatitis due to the mul-
tiple extrapancreatic organ involvement of this disease [8].
Type 2 AIP is idiopathic duct-centric pancreatitis (IDCP)
or granulocyteepithelial lesion-(GEL-) positive pancreatitis,
which is rare in Japan and more prevalent in Europe and the
USA. Clinically, the 2 variants present similarly and exhibit a
dramatic response to steroids. Patients with Type 1 AIP tend
to be older, with other organ involvement in 60% of patients
[9]. Both types have distinct clinical profiles [10]. While Type
1 is associated with a raised IgG4 level, Type 2 is not [11].
However, 20% of patients with Type 1 AIP are seronegative
[9].
The diagnosis of autoimmune pancreatitis in the early
stages was guided by fulfilling the Japanese Pancreas Society’s
minimal consensus criteria. The Mayo Clinic in seeking to
expand the diagnostic criteria proposed also looking for
other organ involvement and response to steroid therapy
in addition to the Japanese criteria—this is known as the
HISORt criteria [5].
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Figure 2: CT abdomen revealing a bulky pancreatic head.
Figure 3: Portal vein narrowed with evidence of impingement on CT axial and sagittal images.
Figure 4: Endoscopic retrograde cholangiopancreatography (ERCP) images with dilated biliary tree down to a strictured distal bile duct.
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Figure 5: An irregular hypoechoic area within the head of the pan-
creas above, which the common bile duct tapered.
Figure 6: EUS-guided FNA of the pancreatic mass.
Clinically, AIP usually presents with upper abdominal
pain, jaundice, and weight loss. Up to 50% of AIP presents
with glucose intolerance [12]. Global pancreatic enlargement
has been regarded as a main feature and has been described
in the literature as “sausage-shaped” enlargement [13]. Our
patient presented with upper abdominal pain, jaundice, and
weight loss, similar presenting features of pancreatic cancer.
His CT abdomen described a “sausage-shaped” enlargement
of the pancreas. He also had a normal calibre pancreatic duct
on ERCP. The Japanese diagnostic criterion for AIP requires
demonstration of irregular narrowing of the main pancreatic
duct on ERCP which he did not have [14].
EUS-guided FNA is a useful diagnostic tool to aid the
diagnosis of pancreatic cancer. However, because of the small
sample size obtained by this method, definitive diagnosis is
sometimes difficult [14]. For this reason, EUS-guided core
biopsy is recommended [15]. In this case, histology from the
first EUS-guided FNA of the head of the pancreas showed
loose fibrous stromal tissue with lymphocytic inflammation
which was supportive of an inflammatory sclerosing process.
The clinical suspicion of a neoplastic process led to a repeat
EUS-guided FNA. This repeat FNA of the head of the
pancreas, using a cellblock preparation technique, confirmed
features of adenocarcinoma along with benign pancreatic
Figure 7: Histopathology revealed carcinoma with squamous dif-
ferentiation and some admixed tumour cells containing intracyto-
plasmic mucin.
Figure 8: Histopathology of areas with gland formation (adenocar-
cinoma).
Figure 9: Histopathology showed inflammatory, sclerosing process
involving benign region of pancreatic tissue. There was fibrosis
atrophy of exocrine elements and lymphoplasmacytic inflammation.
Residual pancreatic islets are also present.
tissue demonstrating a sclerosing pancreatitis pattern with
many IgG4-positive cells.
Differentiating pancreatic cancer from autoimmune pan-
creatitis can be difficult and requires a combination of
clinical, serological, morphological, and histological features.
Fluctuating obstructive jaundice, raised IgG4 levels, delayed
enhancement of the pancreas, and capsule-like rim enhance-
ment of the enlarged pancreas suggest AIP rather than pan-
creatic cancer. Presence of other organ involvement such as
bilateral salivary gland swelling, retroperitoneal fibrosis, and
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hilar or intrahepatic sclerosing cholangitis also favours AIP.
Pancreatic duct features ofAIP onERCPare>3 cmnarrowing
of main pancreatic duct, skip lesions of the main pancreatic
duct, and <5mm upstream dilatation of the main pancreatic
duct [3, 16, 17]. Despite numerous features, in 30% of patients
withAIP, the diagnosis cannot be confirmedwithout a steroid
trial, pancreatic core biopsy, or surgical resection [15].
The patient presented represents an even more difficult
group of patients who may have cancer in the setting of
autoimmune pancreatitis. Several reports have been pub-
lished describing pancreatic cancer in the setting of AIP
[18–21]. Amongst the reports were a patient who devel-
oped metastatic carcinoma following a recent diagnosis of
autoimmune pancreatitis and another elderly gentleman who
developed pancreatic cancer 3 years following a diagnosis
of AIP, for which steroid therapy induced a remission. A
recent review assessing the risk of pancreatic cancer in the
setting of autoimmune pancreatitis in 28 patients found that
82% of patients with autoimmune pancreatitis had pancreatic
intraepithelial neoplasia (PanIN). Of 84 patients with AIP at
their institution, there were 2 cases of pancreatic carcinoma at
6 and 10 years after diagnosis [22].They concluded that AIP is
associated with an increased risk of malignancy, and further
studies are needed. This case along with other similar cases
stresses the need for vigilance and close followup of patients
in the setting of AIP.
4. Conclusion
Autoimmune pancreatitis mimics pancreatic carcinoma clin-
ically and radiologically. Though efforts have been made to
develop strategies to distinguish between AIP and pancre-
atic cancer, cases like these represent a complex diagnostic
dilemma.
Serum markers of AIP and pancreatic cancer are not
always helpful in aiding the diagnosis of both conditions,
and EUS can be associated with sampling errors but offers
potential for diagnostic information that greatly assists in
operative and nonoperative decision making.
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